...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Ingenol mebutate: a new option for actinic keratosis treatment.
【24h】

Ingenol mebutate: a new option for actinic keratosis treatment.

机译：甲磺酸丁二醇酯：治疗光化性角化病的新选择。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Actinic keratosis, one of the most common dermatological pathologies manifests as ultraviolet- or sun-induced macules, papules or plaques, and is considered a biomarker for the risk of skin cancer. Ingenol mebutate (Picato?), extracted from the sap of the Euphorbia peplus plant, is a small molecule with a unique mechanism of action involving direct cytotoxicity and immune stimulation. In 2012, ingenol mebutate was approved by the FDA and the EMA for the treatment of actinic keratosis. In phase III trials, ingenol mebutate gel applied topically once daily at 0.015% for 3 days or 0.05% for 2 days, respectively, significantly reduced head and non-head actinic keratosis lesions. Adverse events were mostly mild or moderate. Local skin responses elicited by the treatment, i.e., erythema, flaking/scaling and crusting, were transient, and resolved spontaneously without sequelae. Adherence to the therapy can be facilitated by the short duration of the treatment.
机译：光化性角化病是最常见的皮肤病病理学之一，表现为紫外线或阳光引起的黄斑，丘疹或斑块，被认为是皮肤癌风险的生物标志物。甲磺酸丁二醇酯（Picato？）是从大戟一品植物的汁液中提取的，是一种小分子，具有独特的作用机制，涉及直接的细胞毒性和免疫刺激。 2012年，甲磺酸丁二醇酯被FDA和EMA批准用于治疗光化性角化病。在III期试验中，丁香酚甲磺酸丁酯凝胶每天一次分别以0.015％的剂量连续3天或0.05％的剂量连续2天局部施用一次，可显着减少头部和非头部的光化性角化病病变。不良事件多为轻度或中度。通过治疗引起的局部皮肤反应，即红斑，剥落/结垢和结s是短暂的，并且自发缓解，没有后遗症。短期的治疗可以促进对治疗的依从性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号